首頁 > 市場調查報告書 > 醫療設備

導管

脈衝場消融市場:按治療領域.按產品組成.按應用領域.按消融源.按關鍵地區.主要參與者的市場份額:行業趨勢和全球預測2023-2035 年

市場調查報告書

商品編碼

1358247

脈衝場消融市場:按治療領域.按產品組成.按應用領域.按消融源.按關鍵地區.主要參與者的市場份額:行業趨勢和全球預測2023-2035 年

Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Areas, Source of Ablation, and Key Geographical Regions: Market Share of Key Companies, Industry Trends and Global Forecasts, 2023-2035

出版日期: 2023年09月27日 | 出版商:

Roots Analysis | 英文 325 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

心房顫動 (AF) 是全世界男性和女性中最常見的持續性心律不整。在一般人群中，心房顫動的盛行率往往隨著年齡的增長而增加。被診斷為心房顫動的患者中風的風險高出五倍，死亡的風險高出兩倍。根據 2019 年全球疾病、傷害和風險因素負擔研究，全球有 5,970 萬名患者受到心房顫動的影響。世界人口老化可能會迅速增加心房顫動的盛行率，因為老年人罹患心房顫動的風險更高。在美國，大約 9% 的 65 歲以上老年人患有心房顫動。在歐洲，心房顫動已成為主要的公共衛生問題之一，其盛行率在過去十年中翻了一番。歐洲國家正快速老化，預計未來10年心房顫動患者數將增加70%。此外，心房顫動檢測和診斷的改善也導致了該疾病報告病例數量的增加。此外，心房顫動盛行率的迅速增加與現代生活方式的多種危險因子有關。這些危險因子包括高血壓、糖尿病、吸菸、飲酒、肥胖、缺乏運動和心理壓力。脈衝場消融是一種非熱治療，已被證明是心房顫動患者的安全治療方法。

目前，有幾種脈衝場消融裝置可供使用或正在開發中，用於心血管、腫瘤、呼吸系統和皮膚疾病等治療應用。特別是，脈衝磁場消融裝置對心肌組織具有選擇性，在治療和管理心律不整方面具有高效能，同時降低食道損傷、肺靜脈狹窄和呼吸神經麻痺的風險。在不同類型的心律不整中，PFA 消融是治療心房顫動（持續性和陣發性）的一種行之有效的方法。心房顫動的特徵是心臟心房（上腔室）心跳不規則，阻止血液流向心室（下腔室）。PFA消融主要涉及肺靜脈隔離（PVI），它針對並隔離肺靜脈，肺靜脈往往是引發心房顫動的異常電訊號來源，讓心臟維持正常節律，目的是找回肺靜脈。在 PVI 手術中，帶有電極的導管會經由血管引入心臟。這些導管被引導到肺靜脈中，電極將受控的電脈衝傳送到肺靜脈周圍的組織。這些電脈衝形成病變或疤痕組織，阻止異常電訊號到達心房的其他部分。我們想強調的是，脈衝場消融不僅適用於心房顫動的治療，也適用於其他心律不整，如室性心搏過速和心房撲動。

在腫瘤學領域，脈衝場消融已被用於治療多種實體腫瘤，包括惡性腫瘤。透過施加電脈衝改變腫瘤微環境、殺死腫瘤細胞並招募免疫系統抑制腫瘤生長和侵襲，可以誘導對腫瘤的抑製作用。此外，以氣道發炎為特徵的慢性支氣管炎可以透過使用 PFA 靶向消融支氣管內的黏液產生細胞來治療。脈衝場消融在皮膚科方面取得了重大進展，提供了一種精確去除皮膚病灶（包括良性和癌前生長物）的有效方法。這種消融技術的組織選擇性保留了皮膚的去細胞膠原基質，並允許靶向細胞再生。

考慮到心房顫動的盛行率不斷上升、不可逆電穿孔消融的高效性和安全性，預計在 2023-2035 年預測期內，脈衝場消融的市場規模將達到 40% 左右，預計複合年增長率為按治療領域來看，心血管疾病領域預計將在2023年佔據脈衝場消融市場的大部分市場份額，而這一趨勢預計在整個預測期內保持不變。

本報告探討了全球脈衝場消融市場，包括市場概述、治療領域趨勢、產品組件、應用領域、消融源、地區趨勢以及參與市場的公司概況。

INTRODUCTION

Pulsed field ablation market, a growing segment of the cardiac ablation market, is anticipated to grow at a compounded annual growth rate (CAGR) of ~40% during the forecast period 2023-2035.

Over the years, medical researchers and practitioners have actively pursued the development of minimally invasive procedures that are less painful, have shorter recovery periods, and offer improved patient outcomes. Such techniques have been able to carve out a niche in the huge atrial fibrillation market. Traditional treatment methods involving surgical procedures, though effective, are accompanied with a wide range of drawbacks, including extensive scarring, longer hospital stays, and a higher risk of complications. As a result, medical experts have turned their attention to ablation therapies, which involve the use of an energy source to destroy the abnormal tissues in the body without the need for invasive surgeries. Currently, several tissue ablation techniques are being employed for the treatment of a wide range of disease indications. However, the conventional ablation methods often rely on thermal energy which can potentially lead to tissue overheating, leading to necrosis of the surrounding healthy tissue. Moreover, these techniques are associated with post-procedural pain and discomfort that impact the patient's quality of life during recovery. As the limitations of traditional ablation methods became apparent, the demand for safer and more effective alternatives led to the emergence of pulsed field ablation (PFA).

Pulsed field ablation harnesses high-voltage electrical pulses delivered in short bursts. This non-thermal ablation process allows for precise targeting of abnormal tissues without causing collateral damage to surrounding healthy cells. By avoiding tissue overheating and charring, PFA ablation significantly reduces the risk of complications and post-procedural discomfort. Despite its applications across diverse medical specialties, pulsed field ablation has particularly shown significant promise in the treatment of cardiac rhythm-related disorders, including atrial fibrillation and ventricular tachycardia. Cardiac ablation through PFA involves the precise application of pulsed field electrical energy to create small scars in the cardiac tissue, effectively blocking irregular electrical signals and restoring a regular heartbeat. According to the Framingham Heart Study, over the past 50 years, the prevalence of atrial fibrillation has increased by three-fold. Owing to the rising disease burden of atrial fibrillation, as well as the ongoing research and development efforts to expand the applications of pulsed field ablation beyond cardiac ablation, the market is anticipated to witness remarkable market growth during the forecast period.

SCOPE OF THE REPORT

"The Pulsed Field Ablation Market: Distribution by Therapeutic Area (Cardiovascular Disorders, Oncological Disorders, Respiratory Disorders and Dermatological Disorders), Product Components (Catheters and Generators), Application Areas (Ablation, and Ablation and Mapping), Source of Ablation (Pulsed Field Energy, Pulsed Field and Radiofrequency Energy, and Pulsed Field and Cryoablation Energy), Key Geographical Regions (North America, Europe and Asia-Pacific): Market Share of Key Companies, Industry Trends and Global Forecasts, 2023-2035 report" features an extensive study of the current market landscape, market size and future opportunities associated with this industry, for the given forecast period. The market research report highlights the efforts of several stakeholders engaged in this emerging and rapidly evolving segment of the medical devices industry. Key takeaways of the pulsed field ablation market report are briefly discussed below.

Surging Prevalence of Atrial Fibrillation, a Key Indication for Pulsed Field Ablation

Atrial Fibrillation (AF) is the most commonly occurring sustained cardiac arrhythmia affecting both men and women, across the globe. Its prevalence tends to rise with age in the general population. , Patients diagnosed with atrial fibrillation face a five-fold higher risk of stroke and a two-fold increased risk of death. According to the Global Burden of Disease, Injury and Risk Factor Study 2019, 59.7 million patients were afflicted with atrial fibrillation, globally. , Since the elderly population is at higher risk of developing atrial fibrillation, the rising ageing world population poses a threat of surged AF prevalence. In the US, around 9% of the population aged 65 and above is suffering from atrial fibrillation. In Europe, atrial fibrillation has emerged as one of the key public health problems, with its prevalence doubling over the last decade. Owing to the rapidly growing ageing population in the European countries, a 70% increase in the number of atrial fibrillation patients has been projected, over the next decade. Further, improved detection and diagnosis of atrial fibrillation has contributed to the growing number of reported cases of this disorder. Moreover, there are multiple modern lifestyle-related risk factors that play a role in the rapidly increasing prevalence of atrial fibrillation. These risk factors include hypertension, diabetes mellitus, smoking, alcohol consumption, obesity, lack of physical activity and psychological stress. Pulsed field ablation, a non-thermal modality, is proving to be a safe procedure for atrial fibrillation patients.

Applications of Pulsed Field Ablation Technology for Cardiac Ablation

At present, several pulsed field ablation devices are available / being developed for therapeutic applications across cardiovascular disorders, oncological disorders, respiratory disorders, and dermatological disorders. In particular, pulsed field ablation devices have demonstrated high efficacy in treating and managing cardiac arrhythmias, while demonstrating selectivity for myocardial tissue and reducing the risk of esophageal injuries, pulmonary vein stenosis and phrenic nerve palsy. Amongst the various types of cardiac arrhythmias, PFA ablation is a proven modality for managing atrial fibrillation (persistent and paroxysmal), which is characterized by irregular beating of the atria (upper chambers) of the heart, due to which blood does not flow to the ventricles (lower chambers). The PFA ablation procedure primarily involves pulmonary vein isolation (PVI) procedure, which aims to restore normal heart rhythm by targeting and isolating the pulmonary veins, which are often the source of abnormal electrical signals that trigger atrial fibrillation. During the PVI procedure, catheters with electrodes are introduced into the heart through blood vessels. These catheters are guided to the pulmonary veins, and the electrodes deliver controlled electrical pulses to the tissue surrounding the pulmonary veins. The electrical pulses create lesions or scar tissue, which block the abnormal electrical signals from propagating to the rest of the atria. It is worth highlighting that beyond atrial fibrillation, the potential application of pulsed field ablation for the treatment of other cardiac arrythmias, including ventricular tachycardia and atrial flutter remains less explored.

Pulsed Field Ablation Transforming Treatment for Oncology and Other Indications

In the field of oncology, pulsed field ablation has been used for the treatment of a wide range of solid tumors, including malignant tumors. Application of electrical pulses can alter the tumor microenvironment, inducing an inhibitory effect on tumors by killing the tumor cells and mobilizing the immune system to suppress tumor growth and invasion. In addition, chronic bronchitis, characterized by inflammation of the airways, can be treated through PFA's targeted ablation of the mucus producing cells lining the inner walls of bronchi. Pulsed field ablation has made significant strides in dermatology, providing an effective approach for precisely removing skin lesions, including both benign and pre-cancerous growths. The tissue selectivity of this type of ablative technology spares the non-cellular collagen foundation of the skin, allowing regeneration of target cells.

Advantages of Pulsed Field Ablation Over Thermal Ablation

Multiple beneficial attributes of pulsed field ablation technology render it a higher safety profile as compared to other thermal ablation techniques. One of the distinguishing features of pulsed field ablation is its tissue-selective functionality, making it particularly valuable in facilitating cardiac ablation procedures by mitigating risks of phrenic palsy and esophageal injury. Even while targeting the cardiomyocytes, this technique spares stromal proteins from alterations, thereby preventing unintended coagulative necrosis and ensuring a more precise and controlled tissue ablation. Further, the delivery of pulsed field energy, whether through one-shot or point-by-point ablation procedures, creates transmural and durable atrial lesions, which effectively reduces the occurrence of pulmonary vein reconnection. , Depending on the specific medical condition and patient's need, electrophysiologists can tailor the electroporation procedure by varying various electrical parameters, such as voltage, number of pulses, pulse width, pulse shape, pulse delay and frequency. It is important to note that pulsed field ablation utilizes apoptosis to induce cell death, leading to a non-inflammatory response and quicker post-procedure recovery time.

Current Pulsed Field Ablation Market Landscape

The pulsed field ablation market features the presence of more than 45 pulsed field ablation devices. Of these, close to 90% of the devices comprise of ablation catheter as an intrinsic part of their product offering. Further, 39 pulsed field ablation devices are currently under various stages of development. In addition, the pulsed field ablation market features 35 companies that possess the necessary expertise to develop and commercialize pulsed field ablation devices. Currently, more than 40% of the pulsed field ablation companies engaged in this industry are small companies, with less than 50 employees. In terms of geographical presence, more than 50% of the pulsed field ablation companies are headquartered in North America. However, it is interesting to note that the majority of the pulsed field ablation devices have received regulatory approval in Europe.

Currently Commercialized Pulsed Field Ablation Devices

At present, seven pulsed field ablation devices have received commercialization approval from various regulatory bodies around the globe. Of these, four devices, namely FARAPULSE™ Pulsed Field Ablation System (Boston Scientific), Affera™ Mapping and Ablation System (Medtronic), RheOx® system (Galvanize Therapeutics) and CENTAURI™ system (Galvanize Therapeutics) are available in Europe. FARAPULSE™ was the first PFA ablation system to receive CE mark in EU to treat atrial fibrillation and remained the only such system till the approval of CENTAURI™ in August 2022. Further, Medtronic's Affera™ is the latest pulsed field ablation catheter to receive CE mark in March 2023.

Further, two pulsed field ablation devices are approved in the US; these are Aliya™ system (Galvanize Therapeutics) for soft tissue ablation and CellFX System (Pulse Biosciences) for dermatological procedures. It is worth highlighting that NanoKnife System developed by AngioDynamics is the only pulsed field ablation device presently approved in China.

Pulsed Field Ablation: Safety and Efficacy in Clinical Studies

More than 70% of the commercialized PFA ablation devices are undergoing clinical trials in regions where they have not yet received approval. The ADVENT pivotal trial, being conducted at 34 locations across US, aims to evaluate the effectiveness of FARAPULSE™ Pulsed Field Ablation by Boston Scientific for the treatment of paroxysmal atrial fibrillation. In addition, a pilot-scale clinical trial, SPACE AF, is being carried out in Canada to evaluate the safety and efficacy of the CENTAURI™ system. , Further, Medtronic's PulseSelect™ Pulsed Field Ablation System is currently being evaluated in PULSED AF, a multi-center, non-randomized, global clinical trial, to assess its effectiveness for the treatment of atrial fibrillation. The device exceeded its performance goal with negligible side effects, thus proving its efficacy. In fact, the clinical study evaluating PulseSelect™ Pulsed Field Ablation System reported a primary adverse events rate of 0.7%, one of the lowest amongst those recorded for any prior FDA Investigational Device Exemption (IDE) trial for atrial fibrillation ablation device. In addition, there were no reported events of esophageal injury, pulmonary vein stenosis or phrenic nerve damage. It is worth highlighting that three pulsed field ablation devices, namely FARAPULSE™ Pulsed Field Ablation System (Boston Scientific), PulseSelect™ Pulsed Field Ablation System (Medtronic) and RheOx® system (Galvanize Therapeutics) have received breakthrough designation from the FDA. ,

Pulsed Field Ablation Market: Cardiovascular Disorders Marget Segment to hold the Largest Market Share

Given the increasing prevalence of atrial fibrillation, high efficacy and safety profile of ablation through irreversible electroporation, the pulsed field ablation market size is anticipated to grow at an annualized rate (CAGR) of nearly 40% during the forecast period 2023-2035. It is worth highlighting that, in terms of therapeutic area, cardiovascular disorders segment is expected to capture the majority market share in the pulsed field ablation market in 2023 and this trend is likely to remain unchanged throughout the forecast period.

Leading Pulsed Field Ablation Companies

Examples of key pulsed field ablation companies (device developers which have also been profiled in this market report) include (in alphabetical order) Abbott, AccuPulse Medical, Acutus Medical, AngioDynamics, Arga Medtech, AtriAN Medical, Aurigen Medical, Biosense Webster, Boston Scientific, CathRx, ElectroPhysiology Frontiers, EnChannel Medical, Galvanize Therapeutics, Hangzhou Dinova EP Technology, Kardium, Medtronic, Mirai Medical, Pulse Biosciences and Tianjin Intelligent Health Medical. This market report includes an easily searchable excel database of all the pulsed field ablation companies worldwide.

Recent Developments

Although the first direct current ablation was performed during the 1980s, the field gained momentum only after 2011, when PFA focused research to treat atrial fibrillation was initiated. Several developments have taken place in the field of pulsed field ablation, over the past few years. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have been outlined in our analyses.

In July 2023, the 9th World Congress on Cardiology and Cardiovascular Therapeutics was held in Vancouver, Canada.
In May 2023, Pulse Biosciences raised an amount of USD 65 million in a private placement round. The round was led by Robert W. Duggan, executive chairman at Pulse Biosciences. The proceeds from the round will be utilized for the development of the company's proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for the treatment of atrial fibrillation.
In March 2023, Medtronic received CE mark approval for the Affera™ Mapping and Ablation System for the treatment of atrial fibrillation. The system includes Sphere-9™ Catheter and Affera™ Prism-1 Mapping Software.

The market report presents an in-depth analysis, highlighting the capabilities of various pulsed field ablation companies, across different geographies. Amongst other elements, the market research report features:

A preface providing an introduction to the full report, Pulsed Field Ablation Market, 2023-2035.
An outline of the systematic research methodology adopted to conduct the study on pulsed field ablation market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall pulsed field ablation market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the key insights captured during our research, offering a high-level view on the current state of the pulsed field ablation market and its likely evolution in the short to mid and long term.
A general overview of pulsed field ablation, highlighting details on different types of ablation techniques. It also features details regarding various types of thermal and non-thermal ablation techniques. Further, it provides information on the various components of pulsed field ablation system, as well as its historical evolution, mechanism of action, therapeutic applications and advantages.
An overview of the current market landscape of pulsed field ablation devices based on relevant parameters, such as product components (ablation catheter, ablation generator, mapping software and others), shape of catheter (circular, linear, flower and basket, spherical and annular), configuration of catheter (open loop and closed loop), type of catheter (by irrigation) (irrigated, non-irrigated), catheter shaft diameter (less than 8 Fr, 8-10 Fr and more than 10 Fr), number of electrodes (less than 6, 6-10 and more than 10), electrical polarity (unipolar, bipolar, quadrapolar), source of ablation (PF, PF and RF energy, and PF and Cryoablation energy), status of development (commercialized and under development), application area (ablation only and ablation and mapping), and target therapeutic area (cardiovascular disorders, oncological disorders, respiratory disorders and dermatological disorders). Further, the chapter features landscape of pulsed field ablation device developers on the basis of relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), type of developer (industry and non-industry) and company ownership (privately held and publicly listed).
An insightful product competitiveness analysis of pulsed field ablation devices, based on player strength (based on years of experience, company size and number of devices offered), product competitiveness (based on application area, source of ablation, electrical polarity and special designation received) and status of development.
Elaborate profiles of prominent pulsed field ablation companies (shortlisted based on most advanced stage of development) engaged in offering PFA ablation devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), product portfolio, recent developments and an informed future outlook.
Tabulated profiles of key pulsed field ablation companies (shortlisted based on stage of development, for North America and Europe, the companies which have products in pilot stage clinical trial have been included, while for Asia-Pacific, companies for which information was available have been profiled) that are engaged in development of PFA ablation devices. Each tabulated profile features an overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives) and information on its product portfolio.
A detailed analysis of the recent developments and initiatives reported in pulsed field ablation market. The chapter features insightful analysis of the partnerships that have been inked within the global pulsed field ablation market since 2015, based on several relevant parameters such as year of partnership, type of partnership (mergers and acquisitions, product / technology integration agreement, product / technology utilization agreement, product development agreement, distribution agreement, clinical trial agreement, research agreement, service alliance), type of solution (PFA system, mapping system, integrated system, other systems), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of deals inked) and regional distribution of partnership activity. The chapter also features detailed analysis of funding and investments raised by pulsed field ablation companies, based on relevant parameters such as year of funding, type of funding, amount invested (USD Million), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and regional distribution of funding.
An insightful analysis of patents filed / granted for pulsed field ablation since 2009, taking into consideration various relevant parameters, such as type of patent, patent application year, patent publication year, geographical location, type of player, patent age, publication time, top CPC symbols, leading players (in terms of number of patents filed / granted). Further, the chapter includes a detailed patent benchmarking analysis.
A detailed analysis of global events attended by the companies engaged in the pulsed field ablation industry, based on relevant parameters such as year of event, type of event, event platform, event organizer, location of event, most active players, speakers and designations (in terms of number of events).
An in-depth analysis of cardiac mapping and navigation device developers, based on relevant parameters such as year of establishment, company size (in terms of number of employees) and location of headquarters. The chapter also features an analysis of the likelihood of partnership of cardiac mapping and navigation device developers with pulsed field ablation device developers.
An in-depth analysis of the factors that can impact the growth of pulsed field ablation market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity for pulsed field ablation companies over the next decade. We have extensively studied the historical market data within this industry, in order to develop a deeper understanding of the evolutionary market trends. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The market report also features the likely distribution of the historical, current and forecasted opportunity within the pulsed field ablation market across various segments, such as therapeutic area (cardiovascular disorders, oncological disorders, respiratory disorders and dermatological disorders), product components (catheter and generator), application area (ablation, and ablation and mapping) and source of ablation (pulsed field energy, pulsed field and radiofrequency energy, and pulsed field and cryoablation energy) and geography (North America, Europe and Asia-Pacific). In addition, this report features the current and forecasted sales revenues of leading device developers engaged in this domain. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's market growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this market report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market over the forecast period, the market report also provides our independent view of various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What is pulsed field ablation?

Answer: Pulsed field ablation is a non-thermal ablation modality that destabilizes cell membrane by forming irreversible pores, eventually leading to cell death. The current pulsed field ablation technology is an adaptation of direct current ablation, which was first used to treat cardiac arrhythmia in the 1980s.

Question 2: How does PFA ablation work?

Answer: Pulsed field ablation operates on the mechanism of irreversible electroporation. When pulsed electric fields are applied to a cell, its intracellular charged species get redistributed, disrupting the transmembrane potential. This leads to the formation of artificial nanopores, hindering the cell's ability to maintain homeostasis. If the loss of homeostasis is of sufficient magnitude or duration, the cell cannot restore normal function and dies through either immediate necrosis or apoptosis.

Question 3: How is PFA performed?

Answer: Pulsed field ablation delivers short bursts of high amplitude electric current to kill abnormal tissues. In order to perform the ablation, a catheter is introduced into the human body, through a vein (femoral vein, for instance). Then the catheter is directed to the target organ (where ablation is to be performed) to ablate the abnormally functioning cells by creating transmural lesions.

Question 4: What are the benefits of pulsed field ablation?

Answer: Pulsed field ablation offers numerous benefits over conventional ablation techniques. These include:

High tissue-selectivity
Significantly less risk of collateral organ damage
Improved pulmonary vein isolation durability, thereby preventing recurrence of arrhythmia
Quicker post-procedure recovery
Reduced procedure duration
Lower contact dependency

Question 5: What is pulsed magnetic field radiofrequency ablation?

Answer: Pulsed magnetic field radiofrequency ablation is an innovative technology that delivers radiofrequency oscillations at a rate of pulses per second. Such devices offer greater flexibility to electrophysiologists by allowing them to toggle between energy sources, while performing the ablation procedure.

Question 6: When will pulsed field ablation be available?

Answer: Pulsed field ablation is currently available in Europe, with four commercialized devices in the market, of which three are approved for the treatment of atrial fibrillation, while one system is available for treating patients with chronic bronchitis. In the US, no pulsed field ablation device is commercially available for the treatment of atrial fibrillation. However, two PFA systems are approved for other indications in the US.

Question 7: What is the success rate of pulsed field ablation?

Answer: Several clinical studies have proven that the success rate of pulsed field ablation, in terms of freedom from recurrence of cardiac arrhythmias, is relatively higher than conventional ablation techniques. As per the recent results of the PULSED AF clinical trial conducted at 41 locations across the globe, pulsed field ablation device, PulseSelect™ Pulsed Field Ablation System, is associated with success rate of 80% for patients with paroxysmal atrial fibrillation and 81% for the persistent atrial fibrillation patients.

Question 8: Is FARAPULSE FDA approved?

Answer: In 2021, FARAPULSE™ Pulsed Field Ablation System received CE mark approval for commercialization in the European Union (EU). It was the first PFA device to receive market authorization for the treatment of atrial fibrillation. However, it has not yet received approval from the FDA.

Question 9: What is the estimated market growth rate (CAGR) for the pulsed field ablation market?

Answer: The pulsed field ablation market size is anticipated to grow at an annualized rate (CAGR) of nearly 30% during the forecast period 2023-2035.

Question 10: Who are the leading companies in the pulsed field ablation market?

Answer: Examples of key pulsed field ablation companies (device developers which have also been profiled in this market report) include (in alphabetical order) AccuPulse Medical, Acutus Medical, Adagio Medical, AngioDynamics, Arga Medtech, AtriAN Medical, Biosense Webster, Boston Scientific, CardioFocus, CathRx, CRC EP, Galvanize Therapeutics, Gradient Medical, Hangzhou Dinova EP Technology, Kardium, Medtronic, Mirai Medical, Pulse Biosciences and Tianjin Intelligent Health Medical.

CHAPTER OUTLINES

Chapter 1 is a preface providing an introduction to the full report, Pulsed Field Ablation Market, 2023-2035.

Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on pulsed field ablation market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of findings.

Chapter 3 provides an overview of economic factors that impact the overall pulsed field ablation market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.

Chapter 4 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the pulsed field ablation market and its likely evolution in the short to mid and long term.

Chapter 5 provides a general overview of pulsed field ablation, highlighting details on different types of ablation techniques. It also features details regarding various types of thermal and non-thermal ablation techniques. Further, it provides information on the various components of pulsed field ablation system, as well as its historical evolution, mechanism of action, therapeutic applications and advantages.

Chapter 6 is an overview of the current market landscape of pulsed field ablation devices based on relevant parameters, such as product components (ablation catheter, ablation generator, mapping software and others), shape of catheter (circular, linear, flower and basket, spherical and annular), configuration of catheter (open loop and closed loop), type of catheter (by irrigation) (irrigated, non-irrigated), catheter shaft diameter (less than 8 Fr, 8-10 Fr and more than 10 Fr), number of electrodes (less than 6, 6-10 and more than 10), electrical polarity (unipolar, bipolar, quadrapolar), source of ablation (PF Only, PF and RF and PF and Cryoablation), status of development (commercialized and under development), application area (ablation only and ablation and mapping), and target therapeutic area (cardiovascular disorders, oncological disorders, respiratory disorders and dermatological disorders). Further, the chapter features landscape of pulsed field ablation device developers on the basis of relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), type of developer (industry and non-industry) and company ownership (privately held and publicly listed).

Chapter 7 presents an insightful product competitiveness analysis of pulsed field ablation devices, based on player strength (based on years of experience, company size and number of devices offered), product competitiveness (based on application area, source of ablation, electrical polarity and special designation received) and status of development.

Chapter 8 includes elaborate profiles of prominent players (shortlisted based on most advanced stage of development) engaged in offering pulsed field ablation devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), product portfolio, recent developments and an informed future outlook.

Chapter 9 presents ttabulated profiles of key players (shortlisted based on stage of development, for North America and Europe, the companies which have products in pilot stage clinical trial have been included, while for Asia-Pacific, companies for which information was available have been profiled) that are engaged in development of pulsed field ablation devices. Each tabulated profile features an overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives) and information on its product portfolio.

Chapter 10 provides a detailed analysis of the recent developments and initiatives reported in pulsed field ablation market. The chapter features insightful analysis of the partnerships that have been inked within the global pulsed field ablation market since 2015, based on several relevant parameters such as year of partnership, type of partnership (mergers and acquisitions, product / technology integration agreement, product / technology utilization agreement, product development agreement, distribution agreement, clinical trial agreement, research agreement, service alliance), type of solution (PFA system, mapping system, integrated system, other systems), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of deals inked) and regional distribution of partnership activity. The chapter also features detailed analysis of funding and investments raised by pulsed field ablation companies, based on relevant parameters such as year of funding, type of funding, amount invested (USD Million), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and regional distribution of funding.

Chapter 11 presents an insightful analysis of patents filed / granted for pulsed field ablation since 2009, taking into consideration various relevant parameters such as type of patent, patent application year, patent publication year, geographical location, type of player, patent age, publication time, top CPC symbols, leading players (in terms of number of patents filed / granted). Further, the chapter includes a detailed patent benchmarking analysis.

Chapter 12 includes detailed analysis of global events attended by the pulsed field ablation companies, based on relevant parameters such as year of event, type of event, event platform, event organizer, location of event, most active players, speakers and designations (in terms of number of events).

Chapter 13 includes an in-depth analysis of cardiac mapping and navigation device developers, based on relevant parameters such as year of establishment, company size (in terms of number of employees) and location of headquarters. The chapter also features an analysis of the likelihood of partnership of cardiac mapping and navigation device developers with pulsed field ablation device developers.

Chapter 14 presents an in-depth analysis of the factors that can impact the growth of pulsed field ablation market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

Chapter 15 presents a detailed market forecast analysis in order to estimate the existing market size and future opportunity for pulsed field ablation over the next decade. Based on multiple parameters, likely adoption trends and population prevalence of indications, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the historical, current and forecasted opportunity within the pulsed field ablation market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 16 provides detailed projections of the historical, current and future pulsed field ablation market across different geographies, namely North America, Europe and Asia-Pacific.

Chapter 17 provides detailed projections of the historical, current and future pulsed field ablation market across various therapeutic areas, namely cardiovascular disorders, oncological disorders, respiratory disorders, and dermatological disorders.

Chapter 18 provides detailed projections of the historical, current and future pulsed field ablation market across various product components, namely catheters and generators.

Chapter 19 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across product components, namely catheters and generators.

Chapter 20 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across two major application areas, namely ablation and ablation and mapping.

Chapter 21 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across various sources of ablation, namely pulsed field energy, pulsed field and radiofrequency energy, and pulsed field and cryoablation energy.

Chapter 22 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across various geographies, namely North America, Europe and Asia-Pacific.

Chapter 23 provides detailed projections of the historical, current and future pulsed field ablation market for oncological disorders across various geographies, namely North America, Europe and Asia-Pacific.

Chapter 24 provides detailed projections of the historical, current and future pulsed field ablation market for oncological disorders across various product components, namely catheters and generators.

Chapter 25 provides detailed projections of the historical, current and future pulsed field ablation market for oncological disorders across various types of cancer, namely soft-tissue ablative cancers, pancreatic cancer, prostate cancer, non-small cell lung cancer and esophageal cancer.

Chapter 26 provides detailed projections of the historical, current and future pulsed field ablation market for respiratory disorders across various geographies, namely North America, Europe and Asia-Pacific.

Chapter 27 provides detailed projections of the historical, current and future pulsed field ablation market for respiratory disorders across various product components, namely catheters and generators.

Chapter 28 provides detailed projections of the current and future pulsed field ablation market for leading players engaged in this industry.

Chapter 29 summarizes the entire report, highlighting various facts related to contemporary market trends and the likely evolution of the pulsed field ablation market, based on the research and analysis described in the previous chapters.

Chapter 30 is an appendix, which contains tabulated data and numbers for all the figures included in this report.

Chapter 31 is an appendix, which contains a list of companies and organizations mentioned in this report.

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH

METHODOLOGY

2.1 Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related

Factors

2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER

PROJECT SPECIFIC CONSIDERATIONS

3.1 Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Future

Estimates

3.2.2. Currency Coverage
- 3.2.2.1. Overview of Major Currencies

Affecting the Market

3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
- 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
- 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
- 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
- 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Types of Ablation Techniques
5.3. Types of Catheter Ablation Techniques
- 5.3.1. Thermal Ablation Techniques
  - 5.3.1.1. Radiofrequency Ablation
  - 5.3.1.2. Laser Ablation
  - 5.3.1.3. Microwave Ablation
  - 5.3.1.4. Hydrothermal Ablation
  - 5.3.1.5. High-Intensity Focused Ultrasound Ablation
- 5.3.2. Non-Thermal Ablation Techniques
  - 5.3.2.1. Cryoablation
  - 5.3.2.2. Mechanico-Chemical Ablation
  - 5.3.2.3. Pulsed Field Ablation
5.4. Overview of Pulsed Field Ablation Therapy
- 5.4.1. Historical Evolution
- 5.4.2. Mechanism of Action
- 5.4.3. Therapeutic Applications
- 5.4.4. Advantages of Pulsed Field Ablation
5.5. Concluding Remarks

6. PULSED FIELD ABLATION DEVICES: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Pulsed Field Ablation Devices: Overall Market Landscape
- 6.2.1. Analysis by Product Components
- 6.2.2. Analysis by Shape of Catheter
- 6.2.3. Analysis by Configuration of Catheter
- 6.2.4. Analysis by Type of Catheter (by Irrigation)
- 6.2.5. Analysis by Catheter Shaft Diameter
- 6.2.6. Analysis by Number of Electrodes
- 6.2.7. Analysis by Electrical Polarity
- 6.2.8. Analysis by Source of Ablation
- 6.2.9. Analysis by Status of Development
- 6.2.10. Analysis by Application Area
- 6.2.11. Analysis by Status of Development and Location of Clinical Trial
- 6.2.12. Analysis by Target Therapeutic Area and Target Indication
- 6.2.13. Analysis by Status of Development and Target Therapeutic Area
- 6.2.14. Analysis by Location of Clinical Trial and Target Therapeutic Area
- 6.2.15 Analysis by Source of Ablation, Application Area, and Target Therapeutic Area
6.3. Pulsed Field Ablation Device Developers: Overall Market Landscape
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Location of Headquarters
- 6.3.4. Analysis by Company Size and Location of Headquarters (Region)
- 6.3.5. Analysis by Type of Developer
- 6.3.6. Analysis by Company Ownership
- 6.3.7. Analysis by Company

Ownership and Location of Headquarters (Region)

6.3.8. Most Active Players: Analysis by Number of Products

7. PRODUCT COMPETITIVENESS ANALYSIS

7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Product Competitiveness Analysis: Pulsed Field Ablation Devices
- 7.4.1. Pulsed Field Ablation Devices Offered by Players based in North America
- 7.4.2. Pulsed Field Ablation Devices Offered by Players based in Europe
- 7.4.3. Pulsed Field Ablation Devices Offered by Players based in Asia-Pacific
7.5. Concluding Remarks

8. PULSED FIELD ABLATION DEVICE DEVELOPERS: DETAILED

COMPANY PROFILES

8.1. Chapter Overview
8.2. Boston Scientific
- 8.2.1. Company Overview
- 8.2.2. Financial Information
- 8.2.3. Pulsed Field Ablation Portfolio
- 8.2.4. Recent Developments and Future Outlook
8.3. Medtronic
- 8.3.1. Company Overview
- 8.3.2. Financial Information
- 8.3.3. Pulsed Field Ablation Portfolio
- 8.3.4. Recent Developments and Future Outlook
8.4. Galvanize Therapeutics
- 8.4.1. Company Overview
- 8.4.2. Pulsed Field Ablation Portfolio
- 8.4.3. Recent Developments and Future Outlook
8.5. Pulse Biosciences
- 8.5.1. Company Overview
- 8.5.2. Pulsed Field Ablation Portfolio
- 8.5.3. Recent Developments and Future Outlook
8.6. AngioDynamics
- 8.6.1. Company Overview
- 8.6.2. Financial Information
- 8.6.3. Pulsed Field Ablation Portfolio
- 8.6.4. Recent Developments and Future Outlook
8.7. Biosense Webster
- 8.7.1. Company Overview
- 8.7.2. Pulsed Field Ablation Portfolio
- 8.7.3. Recent Developments and Future Outlook
8.8. Acutus Medical
- 8.8.1. Company Overview
- 8.8.2. Financial Information
- 8.8.3. Pulsed Field Ablation Portfolio
- 8.8.4. Recent Developments and Future Outlook
8.9. Kardium
- 8.9.1. Company Overview
- 8.9.2. Pulsed Field Ablation Portfolio
- 8.9.3. Recent Developments and Future Outlook

9. PULSED FIELD ABLATION DEVICE DEVELOPERS: TABULATED

COMPANY PROFILES

9.1. Chapter Overview
9.2. Abbott
9.3. AccuPulse Medical
9.4. Arga Medtech
9.5. AtriAN Medical
9.6. AuriGen Medical
9.7. CathRx
9.8. ElectroPhysiology Frontiers
9.9. EnChannel Medical
9.10. Hangzhou Dinova EP

Technology

9.11. Mirai Medical
9.12. Tianjin Intelligent Health

Medical

10. RECENT DEVELOPMENTS AND INITIATIVES

10.1 Chapter Overview
10.2 Partnerships and

Collaborations

10.2.1. Partnership Models
10.2.2. Pulsed Field Ablation: Partnerships and Collaborations
10.2.3. Analysis by Year of Partnership
10.2.4. Analysis by Type of Partnership
10.2.5. Analysis by Year and Type of Partnership
10.2.6. Analysis by Type of Product
10.2.7. Analysis by Type of Partnership and Type of Solution
10.2.8. Analysis by Therapeutic Area
10.2.9. Analysis by Type of Partnership and Therapeutic Area
10.2.10. Most Active Players: Analysis by Number of Partnerships
10.2.11. Analysis by Geography
- 10.2.11.1. Intercontinental and Intracontinental Agreements
- 10.2.11.2. Local and International Agreements

10.3. Funding and Investments
- 10.3.1. Funding Models
- 10.3.2. Pulsed Field Ablation: Funding

and Investments

10.3.3. Analysis by Year of Investment
- 10.3.3.1. Cumulative Year-wise Trend of Funding Instances
- 10.3.3.2. Cumulative Year-wise Trend of Amount Invested
10.3.4. Analysis by Type of Funding
- 10.3.4.1. Analysis of Funding Instances
- 10.3.4.2. Analysis of Amount Invested
10.3.5. Analysis by Year and Type of Funding
- 10.3.5.1. Analysis of Funding Instances
- 10.3.5.2. Analysis of Amount Invested
10.3.6. Analysis of Funding Instances and Amount Invested by Therapeutic Area
10.3.7. Most Active Players: Analysis by Funding Instances
10.3.8. Most Active Players: Analysis by Amount Raised
10.3.9. Leading Investors: Analysis by Funding Instances
10.3.10. Analysis of Funding Instances and Amount Invested by Geography

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Pulsed Field Ablation: Patent Analysis
- 11.3.1. Analysis by Patent Application Year
- 11.3.2. Analysis by Patent Publication Year
- 11.3.3. Analysis by Type of Patent and Patent Publication Year
- 11.3.4. Analysis by Publication Time
- 11.3.5. Analysis by Patent Jurisdiction
- 11.3.6. Analysis by CPC Symbols
- 11.3.7. Analysis by Type of Applicant
- 11.3.8. Analysis by Patent Age
- 11.3.9. Leading Players: Analysis by Number of Patents
- 11.3.10. Leading Patent Assignees: Analysis by Number of Patents
11.4. Pulsed Field Ablation: Patent Benchmarking Analysis
- 11.4.1. Analysis of Top CPC Codes by Leading Industry Players
- 11.4.2. Analysis of Top CPC Codes by Publication Time
11.5. Pulsed Field Ablation: Patent Valuation

12. GLOBAL EVENTS ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Pulsed Field Ablation: Global Events
- 12.3.1. Analysis by Year of Event
- 12.3.2. Analysis by Type of Event
- 12.3.3. Analysis by Year and Type of Event
- 12.3.4. Analysis by Event Platform
- 12.3.5. Analysis by Location of Event
- 12.3.6. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Areas
- 12.3.7. Most Active Event Organizers: Analysis by Number of Events
- 12.3.8. Most Active Players: Analysis by Number of Events
12.4. Global Events: Speaker Analysis
- 12.4.1. Most Active Speakers: Analysis by Number of Events
- 12.4.2. Analysis by Designation of Speakers
12.5. Concluding Remarks

13. CASE STUDY: POTENTIAL PARTNERS OF PULSED FIELD ABLATION DEVICE DEVELOPERS

13.1. Chapter Overview
13.2. Cardiac Mapping and Navigation Device Developers
- 13.2.1 Analysis by Year of Establishment
- 13.2.2 Analysis by Company Size
- 13.2.3 Analysis by Location of Headquarters
13.3. Likely Partner Analysis
- 13.3.1. Assumptions and Key Parameters
- 13.3.2. Methodology
13.4. Potential Strategic Partners for Cardiac Pulsed Field Ablation Device Developers
- 13.4.1. Cardiac Mapping and Navigation Device Developers: Most Likely Partners
- 13.4.2. Cardiac Mapping and Navigation Device Developers: Likely Partners
- 13.4.3. Cardiac Mapping and Navigation Device Developers: Less Likely Partners

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

14.1. Chapter Overview
14.2. Market Drivers
14.3. Market Restraints
14.4. Market Opportunities
14.5. Market Challenges
14.6. Conclusion

15. GLOBAL PULSED FIELD ABLATION MARKET

15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Pulsed Field Ablation Market, Historical Trends (2018-2022) and Future

Estimates (2023-2035)

15.3.1. Scenario Analysis

15.4. Key Market Segmentations
15.5. Dynamic Dashboard

16. PULSED FIELD ABLATION MARKET, BY GEOGRAPHY

16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
16.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
16.6. Data Triangulation
- 16.6.1. Insights from Secondary Research
- 16.6.2. Insights from In-house Repository
- 16.6.3. Dynamic Dashboard

17. PULSED FIELD ABLATION MARKET, BY THERAPEUTIC AREA

17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Cardiovascular Disorders: Historical Trends (2021-2022) and Forecasted Estimates

(2023-2035)

17.4. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates

(2023-2035)

17.5. Respiratory Disorders: Historical Trends (2020-2022) and Forecasted Estimates

(2023-2035)

17.6. Dermatological Disorders: Historical Trends (2022) and Forecasted Estimates

(2023-2035)

17.7. Data Triangulation
- 17.7.1. Insights from Secondary

Research

17.7.2. Insights from In-house Repository
17.7.3. Dynamic Dashboard

18. PULSED FIELD ABLATION MARKET, BY PRODUCT COMPONENTS

18.1. Chapter Overview
18.2. Forecast Methodology and Key Assumptions
18.3. Catheters: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
18.4. Generators: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Data Triangulation
- 18.5.1. Insights from Secondary

Research

18.5.2. Insights from In-house Repository
18.5.3. Dynamic Dashboard

19. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR DISORDERS, BY PRODUCT COMPONENTS

19.1. Chapter Overview
19.2. Forecast Methodology and Key Assumptions
19.3. Catheters: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
19.4. Generators: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
19.5. Data Triangulation
- 19.5.1. Insights from Secondary Research
- 19.5.2. Insights from In-house Repository
- 19.5.3. Dynamic Dashboard

20. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR

DISORDERS, BY APPLICATION AREA

20.1. Chapter Overview
20.2. Forecast Methodology and Key Assumptions
20.3. Ablation: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
20.4. Ablation and Mapping: Historical Trends (2021-2022) and Forecasted Estimates

(2023-2035)

20.5. Data Triangulation
- 20.5.1. Insights from Secondary Research
- 20.5.2. Insights from In-house Repository
- 20.5.3. Dynamic Dashboard

21. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR

DISORDERS, BY SOURCE OF ABLATION

21.1. Chapter Overview
21.2. Forecast Methodology and Key Assumptions
21.3. Pulsed Field: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
21.4. Pulsed Field and Radiofrequency: Historical Trends (2021-2022) and Future

Estimates (2023-2035)

21.5. Pulsed Field and Cryoablation: Historical Trends (2021-2022) and Future

Estimates (2023-2035)

21.6. Data Triangulation
- 21.6.1. Insights from Secondary Research
- 21.6.2. Insights from In-house Repository
- 21.6.3. Dynamic Dashboard

22. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR

DISORDERS, BY GEOGRAPHY

22.1. Chapter Overview
22.2. Forecast Methodology and Key Assumptions
22.3. North America: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
- 22.3.1. US: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
- 22.3.2. Canada: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
22.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
22.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
- 22.5.1. China: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
- 22.5.2. Japan: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
22.6. Data Triangulation
- 22.6.1. Insights from Secondary Research
- 22.6.2. Insights from In-house Repository
- 22.6.3. Dynamic Dashboard

23. PULSED FIELD ABLATION MARKET FOR ONCOLOGICAL

DISORDERS, BY GEOGRAPHY

23.1. Chapter Overview
23.2. Forecast Methodology and Key Assumptions
23.3. North America: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
23.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
23.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
23.6. Data Triangulation
- 23.6.1. Insights from Secondary Research
- 23.6.2. Insights from In-house Repository
- 23.6.3. Dynamic Dashboard

24. PULSED FIELD ABLATION MARKET FOR ONCOLOGICAL DISORDERS, BY PRODUCT COMPONENTS

24.1. Chapter Overview
24.2. Forecast Methodology and Key Assumptions
24.3. Catheters: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
24.4. Generators: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
24.5. Data Triangulation
- 24.5.1. Insights from Secondary Research
- 24.5.2. Insights from In-house Repository
- 24.5.3. Dynamic Dashboard

25. PULSED FIELD ABLATION MARKET FOR ONCOLOGICAL DISORDERS, BY TYPE OF CANCER

25.1. Chapter Overview
25.2. Forecast Methodology and Key Assumptions
25.3. Soft Tissue Ablative Cancers: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
25.4. Pancreatic Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
25.5. Prostate Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
25.6 Non-Small Cell Lung Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
25.7 Esophageal Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
25.8 Data Triangulation
- 25.8.1. Insights from Secondary Research
- 25.8.2 Insights from In-house Repository
- 25.8.3. Dynamic Dashboard

26. PULSED FIELD ABLATION MARKET FOR RESPIRATORY

DISORDERS, BY GEOGRAPHY

26.1 Chapter Overview
26.2. Forecast Methodology and Key Assumptions
26.3. North America: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
26.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
26.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
26.6. Data Triangulation
- 26.6.1. Insights from Secondary Research
- 26.6.2. Insights from In-house Repository
- 26.6.3. Dynamic Dashboard

27. PULSED FIELD ABLATION MARKET FOR RESPIRATORY

DISORDERS, BY PRODUCT COMPONENTS

27.1 Chapter Overview
27.2. Forecast Methodology and Key Assumptions
27.3. Catheters : Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
27.4. Generators: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
27.5. Data Triangulation
- 27.5.1. Insights from Secondary Research
- 27.5.2. Insights from In-house Repository
- 27.5.3. Dynamic Dashboard

28. PULSED FIELD ABLATION: SALES FORECAST OF LEADING

PLAYERS

28.1. Chapter Overview
28.2. Boston Scientific: Pulsed Field Ablation Sales Forecast (2023-2035)
28.3. Medtronic: Pulsed Field Ablation Sales Forecast (2023-2035)
28.4. Galvanize Therapeutics: Pulsed Field Ablation Sales Forecast (2023-2035)
28.5. AngioDynamics: Pulsed Field Ablation Sales Forecast (2023-2035)

29. CONCLUDING REMARKS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List Of Tables

Table 5.1 Differences between Catheter Ablation and Surgical Ablation
Table 5.2 Types of Catheter Ablation Techniques: Information on Mechanism of Action, Advantages and Disadvantages
Table 6.1 List of Pulsed Field Ablation Devices
Table 6.2 Pulsed Field Ablation Devices: Information on Shape of Catheter, Configuration of Catheter and Type of Catheter (by Irrigation)
Table 6.3 Pulsed Field Ablation Devices: Information on Catheter Shaft Diameter, Number of Electrodes and Electrical Polarity
Table 6.4 Pulsed Field Ablation Devices: Information on Source of Ablation, Status of Development, Phase of Development of Investigational Devices and Application Area
Table 6.5 Pulsed Field Ablation Devices: Information on NCT Number and Location of Clinical Trial
Table 6.6 Pulsed Field Ablation Devices: Information on Target Indication and Target Therapeutic Area
Table 6.7 List of Pulsed Field Ablation Device Developers
Table 8.1 Leading Developers of Pulsed Field Ablation Systems
Table 8.2 Boston Scientific: Company Snapshot
Table 8.3 Boston Scientific: Pulsed Field Ablation Portfolio
Table 8.4 Boston Scientific: Recent Developments and Future Outlook
Table 8.5 Medtronic: Company Snapshot
Table 8.6 Medtronic: Pulsed Field Ablation Portfolio
Table 8.7 Medtronic: Recent Developments and Future Outlook
Table 8.8 Galvanize Therapeutics: Company Snapshot
Table 8.9 Galvanize Therapeutics: Pulsed Field Ablation Portfolio
Table 8.10 Galvanize Therapeutics: Recent Developments and Future Outlook
Table 8.11 Pulse Biosciences: Company Snapshot
Table 8.12 Pulse Biosciences: Pulsed Field Ablation Portfolio
Table 8.13 Pulse Biosciences: Recent Developments and Future Outlook
Table 8.14 AngioDynamics: Company Snapshot
Table 8.15 AngioDynamics: Pulsed Field Ablation Portfolio
Table 8.16 AngioDynamics: Recent Developments and Future Outlook
Table 8.17 Biosense Webster: Company Snapshot
Table 8.18 Biosense Webster: Pulsed Field Ablation Portfolio
Table 8.19 Biosense Webster: Recent Developments and Future Outlook
Table 8.20 Acutus Medical: Company Snapshot
Table 8.21 Acutus Medical: Pulsed Field Ablation Portfolio
Table 8.22 Acutus Medical: Recent Developments and Future Outlook
Table 8.23 Kardium: Company Snapshot
Table 8.24 Kardium: Pulsed Field Ablation Portfolio
Table 8.25 Kardium: Recent Developments and Future Outlook
Table 9.1 Abbott: Company Snapshot and Product Portfolio
Table 9.2 AccuPulse Medical: Company Snapshot and Product Portfolio
Table 9.3 Argá Medtech: Company Snapshot and Product Portfolio
Table 9.4 AtriAN Medical: Company Snapshot and Product Portfolio
Table 9.5 AuriGen Medical: Company Snapshot and Product Portfolio
Table 9.6 CathRx: Company Snapshot and Product Portfolio
Table 9.7 ElectroPhysiology Frontiers: Company Snapshot and Product Portfolio
Table 9.8 EnChannel Medical: Company Snapshot and Product Portfolio
Table 9.9 Hangzhou Dinova EP Technology: Company Snapshot and Product Portfolio
Table 9.10 Mirai Medical: Company Snapshot and Product Portfolio
Table 9.11 Tianjin Intelligent Health Medical: Company Snapshot and Product Portfolio
Table 10.1 Pulsed Field Ablation: List of Partnerships and Collaborations
Table 10.2 Pulsed Field Ablation: List of Funding and Investments
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: Top CPC Codes
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Analysis: List of Leading Patents (by Number of Citations)
Table 12.1 Pulsed Field Ablation: List of Global Events
Table 13.1 List of Cardiac Mapping and Navigation Device Developers
Table 13.2 Likely Partner Analysis: Cardiac Mapping and Navigation Device Developers
Table 30.1 Pulsed Field Ablation Devices: Distribution by Product Components
Table 30.2 Pulsed Field Ablation Devices: Distribution by Shape of Catheter
Table 30.3 Pulsed Field Ablation Devices: Distribution by Configuration of Catheter
Table 30.4 Pulsed Field Ablation Devices: Distribution by Type of Catheter (by Irrigation)
Table 30.5 Pulsed Field Ablation Devices: Distribution by Catheter Shaft Diameter (in Fr)
Table 30.6 Pulsed Field Ablation Devices: Distribution by Number of Electrodes
Table 30.7 Pulsed Field Ablation Devices: Distribution by Electrical Polarity
Table 30.8 Pulsed Field Ablation Devices: Distribution by Source of Ablation
Table 30.9 Pulsed Field Ablation Devices: Distribution by Status of Development
Table 30.10 Pulsed Field Ablation Devices: Distribution by Status of Development and Location of Clinical Trial
Table 30.11 Pulsed Field Ablation Devices: Distribution by Application Area
Table 30.12 Pulsed Field Ablation Devices: Distribution by Target Therapeutic Area and Target Indication
Table 30.13 Pulsed Field Ablation Devices: Distribution by Status of Development and Target Therapeutic Area
Table 30.14 Pulsed Field Ablation Devices: Distribution by Location of Clinical Trial and Target Therapeutic Area
Table 30.15 Pulsed Field Ablation Devices: Distribution by Source of Ablation, Application Area and Target Therapeutic Area
Table 30.16 Pulsed Field Ablation Device Developers: Distribution by Year of Establishment
Table 30.17 Pulsed Field Ablation Device Developers: Distribution by Company Size
Table 30.18 Pulsed Field Ablation Device Developers: Distribution by Location of Headquarters (Region)
Table 30.19 Pulsed Field Ablation Device Developers: Distribution by Location of Headquarters (Country)
Table 30.20 Pulsed Field Ablation Device Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 30.21 Pulsed Field Ablation Device Developers: Distribution by Type of Developer
Table 30.22 Pulsed Field Ablation Device Developers: Distribution by Company Ownership
Table 30.23 Pulsed Field Ablation Device Developers: Distribution by Company Ownership and Location of Headquarters (Region)
Table 30.24 Most Active Players: Distribution by Number of Products
Table 30.25 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in North America
Table 30.26 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in Europe
Table 30.27 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in Asia-Pacific
Table 30.28 Product Competitiveness Analysis of Pulsed Field Ablation Devices: Competitiveness Score of Top Products
Table 30.29 Boston Scientific: Financial Information
Table 30.30 Medtronic: Financial Information
Table 30.31 AngioDynamics: Financial Information
Table 30.32 Acutus Medical: Financial Information
Table 30.33 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2019-2022
Table 30.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 30.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 30.36 Partnerships and Collaborations: Distribution by Type of Product
Table 30.37 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 30.38 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 30.39 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 30.40 Most Active Players: Distribution by Number of Partnerships
Table 30.41 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 30.42 Partnerships and Collaborations: Local and International Agreements
Table 30.43 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2016-2023
Table 30.44 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2016-2023
Table 30.45 Funding and Investments: Distribution of Funding Instances by Type of Funding
Table 30.46 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 30.47 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Table 30.48 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 30.49 Funding and Investments: Distribution of Funding Instances and Amount Invested by Therapeutic Area
Table 30.50 Most Active Players: Distribution by Funding Instances
Table 30.51 Most Active Players: Distribution by Amount Raised
Table 30.52 Leading Investors: Distribution by Funding Instances
Table 30.53 Funding and Investments: Distribution of Funding Instances and Amount Invested by Geography
Table 30.54 Patent Analysis: Distribution by Type of Patent
Table 30.55 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2016-2022
Table 30.56 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, Pre-2016-2023
Table 30.57 Patent Analysis: Distribution by Type of Patent and Patent Publication Year
Table 30.58 Patent Analysis: Distribution by Publication Time
Table 30.59 Patent Analysis: Distribution by Patent Jurisdiction
Table 30.60 Patent Analysis: Distribution by Type of Applicant
Table 30.61 Patent Analysis: Distribution by Patent Age
Table 30.62 Leading Players: Distribution by Number of Patents
Table 30.63 Leading Patent Assignees: Distribution by Number of Patents
Table 30.64 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 30.65 Patent Benchmarking Analysis: Distribution of Publication Time by Patent Characteristics (CPC Codes)
Table 30.66 Pulsed Field Ablation: Patent Valuation
Table 30.67 Global Events Analysis: Cumulative Year-wise Trend, 2018-2023
Table 30.68 Global Events Analysis: Distribution by Type of Event
Table 30.69 Global Events Analysis: Distribution by Year and Type of Event
Table 30.70 Global Events Analysis: Distribution by Event Platform
Table 30.71 Global Events Analysis: Distribution by Location of Event (Region)
Table 30.72 Global Events Analysis: Distribution by Location of Event (Country)
Table 30.73 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Areas
Table 30.74 Most Active Event Organizers: Distribution by Number of Events
Table 30.75 Most Active Participants: Distribution by Number of Events
Table 30.76 Most Active Speakers: Distribution by Number of Events
Table 30.77 Distribution by Designations of Speakers
Table 30.78 Cardiac Mapping and Navigation Device Developers: Distribution by Year of Establishment
Table 30.79 Cardiac Mapping and Navigation Device Developers: Distribution by Company Size
Table 30.80 Cardiac Mapping and Navigation Device Developers: Distribution by Location of Headquarters (Region)
Table 30.81 Cardiac Mapping and Navigation Device Developers: Distribution by Location of Headquarters (Country)
Table 30.82 Cardiac Mapping and Navigation Device Developers: Likely Partners of Cardiac Pulsed Field Ablation Device Developers
Table 30.83 Global Pulsed Field Ablation Market, Historical Trends (2018-2022) and Future Estimates (2023-2035) (USD Million)
Table 30.84 Global Pulsed Field Ablation Market, Forecasted Estimates (2023-2035), Scenario I (USD Million)
Table 30.85 Global Pulsed Field Ablation Market, Forecasted Estimates (2023-2035), Scenario II (USD Million)
Table 30.86 Global Pulsed Field Ablation Market, Forecasted Estimates (2023-2035), Scenario III (USD Million)
Table 30.87 Pulsed Field Ablation Market: Distribution by Geography, 2018, 2023 and 2035
Table 30.88 Pulsed Field Ablation Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.89 Pulsed Field Ablation Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.90 Pulsed Field Ablation Market in Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.91 Pulsed Field Ablation Market: Distribution by Therapeutic Area, 2018, 2023 and 2035
Table 30.92 Pulsed Field Ablation Market for Cardiovascular Disorders, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.93 Pulsed Field Ablation Market for Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.94 Pulsed Field Ablation Market for Respiratory Disorders, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.95 Pulsed Field Ablation Market for Dermatological Disorders, Historical Trends (2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.96 Pulsed Field Ablation Market: Distribution by Product Components, 2018, 2023 and 2035
Table 30.97 Pulsed Field Ablation Market for Catheters, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.98 Pulsed Field Ablation Market for Generators, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.99 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Product Components, 2021, 2023 and 2035
Table 30.100 Pulsed Field Ablation Market for Cardiovascular Disorders using Catheters, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.101 Pulsed Field Ablation Market for Cardiovascular Disorders using Generators, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.102 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Application Area, 2021, 2023 and 2035
Table 30.103 Pulsed Field Ablation Market for Cardiovascular Disorders using Ablation Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.104 Pulsed Field Ablation Market for Cardiovascular Disorders using Ablation and Mapping Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USDMillion)
Table 30.105 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Source of Ablation, 2021, 2023 and 2035
Table 30.106 Pulsed Field Ablation Market for Cardiovascular Disorders using PF Energy-based Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)(USD Million)
Table 30.107 Pulsed Field Ablation Market for Cardiovascular Disorders using PF and RF Energy-based Devices, Historical Trends (2021-2022) and Forecasted Estimates (202-32035)(USD Million)
Table 30.108 Pulsed Field Ablation Market for Cardiovascular Disorders using PF and Cryo Energy-based Devices, Historical Trends (2021-2022) and Forecasted Estimates (223-2035)(USD Million)
Table 30.109 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Geography, 2021, 2023 and 2035
Table 30.110 Pulsed Field Ablation Market for Cardiovascular Disorders in North America, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.111 Pulsed Field Ablation Market for Cardiovascular Disorders in US, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.112 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates(-20232035) (USD Million)
Table 30.113 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)(USD Million)
Table 30.114 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates(-20232035) (USD Million)
Table 30.115 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.116 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (223-2035) (USD Million)
Table 30.117 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates(20244987035) (USD Million)
Table 30.118 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (20-232035) (USD Million)
Table 30.119 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.120 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (20-232035) (USD Million)
Table 30.121 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates(2023-2035) (USD Million)
Table 30.122 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (20-232035) (USD Million)
Table 30.123 Pulsed Field Ablation Market for Cardiovascular Disorders in Asia-Pacific, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.124 Pulsed Field Ablation Market for Cardiovascular Disorders in China, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.125 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates(20244987035) (USD Million)
Table 30.126 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates(-20232035) (USD Million)
Table 30.127 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates(20244987035) (USD Million)
Table 30.128 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.129 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates(20244987035) (USD Million)
Table 30.130 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates(-20232035) (USD Million)
Table 30.131 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates(20244987035) (USD Million)
Table 30.132 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Geography, 2018, 2023 and 2035
Table 30.133 Pulsed Field Ablation Market for Oncological Disorders in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.134 Pulsed Field Ablation Market for Oncological Disorders in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.135 Pulsed Field Ablation Market for Oncological Disorders in Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.136 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Product Components, 2018, 2023 and 2035
Table 30.137 Pulsed Field Ablation Market for Oncological Disorders using Catheters, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.138 Pulsed Field Ablation Market for Oncological Disorders using Generators, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.139 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Type of Cancer, 2018, 2023 and 2035
Table 30.140 Pulsed Field Ablation Market for Soft-tissue Ablative Cancers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.141 Pulsed Field Ablation Market for Pancreatic Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.142 Pulsed Field Ablation Market for Prostate Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.143 Pulsed Field Ablation Market for Non-Small Cell Lung Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.144 Pulsed Field Ablation Market for Esophageal Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.145 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Geography, 2020, 2023 and 2035
Table 30.146 Pulsed Field Ablation Market for Respiratory Disorders in North America, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.147 Pulsed Field Ablation Market for Respiratory Disorders in Europe, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.148 Pulsed Field Ablation Market for Respiratory Disorders in Asia-Pacific, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.149 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Product Components, 2019, 2023 and 2035
Table 30.150 Pulsed Field Ablation Market for Respiratory Disorders using Catheters, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.151 Pulsed Field Ablation Market for Respiratory Disorders using Generators, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Table 30.152 Boston Scientific: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Table 30.153 Medtronic: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Table 30.154 Galvanize Therapeutics: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Table 30.155 AngioDynamics: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)

List Of Figures

Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Recent Developments and Initiatives
Figure 4.3 Executive Summary: Patent Analysis
Figure 4.4 Executive Summary: Global Events Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Types of Ablation Techniques
Figure 5.2 Steps Involved in Pulsed Field Ablation
Figure 5.3 Various Parameters related to Ablative Energy Delivery
Figure 5.4 Historical Evolution of Pulsed Field Ablation Therapy
Figure 5.5 Mechanism of Action: Steps of Irreversible Electroporation
Figure 5.6 Advantages of Pulsed Field Ablation
Figure 6.1 Pulsed Field Ablation Devices: Distribution by Product Components
Figure 6.2 Pulsed Field Ablation Devices: Distribution by Shape of Catheter
Figure 6.3 Pulsed Field Ablation Devices: Distribution by Configuration of Catheter
Figure 6.4 Pulsed Field Ablation Devices: Distribution by Type of Catheter (by Irrigation)
Figure 6.5 Pulsed Field Ablation Devices: Distribution by Catheter Shaft Diameter (in Fr)
Figure 6.6 Pulsed Field Ablation Devices: Distribution by Number of Electrodes
Figure 6.7 Pulsed Field Ablation Devices: Distribution by Electrical Polarity
Figure 6.8 Pulsed Field Ablation Devices: Distribution by Source of Ablation
Figure 6.9 Pulsed Field Ablation Devices: Distribution by Status of Development
Figure 6.10 Pulsed Field Ablation Devices: Distribution by Status of Development and Location of Clinical Trial
Figure 6.11 Pulsed Field Ablation Devices: Distribution by Application Area
Figure 6.12 Pulsed Field Ablation Devices: Distribution by Target Therapeutic Area and Target Indication
Figure 6.13 Pulsed Field Ablation Devices: Distribution by Status of Development and Target Therapeutic Area
Figure 6.14 Pulsed Field Ablation Devices: Distribution by Location of Clinical Trial and Target Therapeutic Area
Figure 6.15 Pulsed Field Ablation Devices: Distribution by Source of Ablation, Application Area and Target Therapeutic Area
Figure 6.16 Pulsed Field Ablation Device Developers: Distribution by Year of Establishment
Figure 6.17 Pulsed Field Ablation Device Developers: Distribution by Company Size
Figure 6.18 Pulsed Field Ablation Device Developers: Distribution by Location of Headquarters (Region)
Figure 6.19 Pulsed Field Ablation Device Developers: Distribution by Location of Headquarters (Country)
Figure 6.20 Pulsed Field Ablation Device Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.21 Pulsed Field Ablation Device Developers: Distribution by Type of Developer
Figure 6.22 Pulsed Field Ablation Device Developers: Distribution by Company Ownership
Figure 6.23 Pulsed Field Ablation Device Developers: Distribution by Company Ownership and Location of Headquarters (Region)
Figure 6.24 Most Active Players: Distribution by Number of Products
Figure 7.1 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in North America
Figure 7.2 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in Europe
Figure 7.3 Product Competitiveness Analysis: Pulsed Field Ablation Devices Offered by Players based in Asia-Pacific
Figure 7.4 Product Competitiveness Analysis of Pulsed Field Ablation Devices: Competitiveness Score of Top Products
Figure 8.1 Boston Scientific: Financial Information
Figure 8.2 Medtronic: Financial Information
Figure 8.3 AngioDynamics: Financial Information
Figure 8.4 Acutus Medical: Financial Information
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2019-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.10 Partnerships and Collaborations: Local and International Agreements
Figure 10.11 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2016-2023
Figure 10.12 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2016-2023
Figure 10.13 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 10.14 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.15 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Figure 10.16 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 10.17 Funding and Investments: Distribution of Funding Instances and Amount Invested by Therapeutic Area
Figure 10.18 Most Active Players: Distribution by Funding Instances
Figure 10.19 Most Active Players: Distribution by Amount Raised
Figure 10.20 Leading Investors: Distribution by Funding Instances
Figure 10.21 Funding and Investments: Distribution of Funding Instances and Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2016-2022
Figure 11.3 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, Pre-2016-2023
Figure 11.4 Patent Analysis: Distribution by Type of Patent and Patent Publication Year
Figure 11.5 Patent Analysis: Distribution by Publication Time
Figure 11.6 Patent Analysis: Distribution by Patent Jurisdiction
Figure 11.7 Patent Analysis: Distribution by Type of Applicant
Figure 11.8 Patent Analysis: Distribution by Patent Age
Figure 11.9 Leading Players: Distribution by Number of Patents
Figure 11.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) Leading Industry Players
Figure 11.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Publication Time
Figure 11.13 Pulsed Field Ablation Devices: Patent Valuation
Figure 12.1 Global Events Analysis: Cumulative Year-wise Trend, 2018-2023
Figure 12.2 Global Events Analysis: Distribution by Type of Event
Figure 12.3 Global Events Analysis: Distribution by Year and Type of Event
Figure 12.4 Global Events Analysis: Distribution by Event Platform
Figure 12.5 Global Events Analysis: Distribution by Location of Event (Region)
Figure 12.6 Global Events Analysis: Distribution by Location of Event (Country)
Figure 12.7 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Areas
Figure 12.8 Most Active Event Organizers: Distribution by Number of Events
Figure 12.9 Most Active Players: Distribution by Number of Events
Figure 12.10 Most Active Speakers: Distribution by Number of Events
Figure 12.11 Distribution by Designations of Speakers
Figure 13.1 Cardiac Mapping and Navigation Device Developers: Distribution by Year of Establishment
Figure 13.2 Cardiac Mapping and Navigation Device Developers: Distribution by Company Size
Figure 13.3 Cardiac Mapping and Navigation Device Developers: Distribution by Location of Headquarters (Region)
Figure 13.4 Cardiac Mapping and Navigation Device Developers: Distribution by Location of Headquarters (Country)
Figure 13.5 Cardiac Mapping and Navigation Device Developers: Likely Partners of Cardiac Pulsed Field Ablation Device Developers
Figure 15.1 Global Pulsed Field Ablation Market, Historical Trends (2018-2022) and Future Estimates (2023-2035) (USD Million)
Figure 15.2 Global Pulsed Field Ablation Market, Forecasted Estimates (2023-2035), Scenario I (USD Million)
Figure 15.3 Global Pulsed Field Ablation Market, Forecasted Estimates (2023-2035), Scenario II (USD Million)
Figure 15.4 Global Pulsed Field Ablation Market, Forecasted Estimates (2023-2035), Scenario III (USD Million)
Figure 15.5 Global Pulsed Field Ablation Market (Dynamic Dashboard Snippet)
Figure 16.1 Pulsed Field Ablation Market: Distribution by Geography, 2018, 2023 and 2035
Figure 16.2 Pulsed Field Ablation Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.3 Pulsed Field Ablation Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.4 Pulsed Field Ablation Market in Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.5 Pulsed Field Ablation Market: Distribution by Geography (Dynamic Dashboard Snippet)
Figure 17.1 Pulsed Field Ablation Market: Distribution by Therapeutic Area, 2018, 2023 and 2035
Figure 17.2 Pulsed Field Ablation Market for Cardiovascular Disorders, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 17.3 Pulsed Field Ablation Market for Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 17.4 Pulsed Field Ablation Market for Respiratory Disorders, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 17.5 Pulsed Field Ablation Market for Dermatological Disorders, Historical Trends (2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 17.6 Pulsed Field Ablation Market: Distribution by Therapeutic Area (Dynamic Dashboard Snippet)
Figure 18.1 Pulsed Field Ablation Market: Distribution by Product Components, 2018, 2023 and 2035
Figure 18.2 Pulsed Field Ablation Market for Catheters, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 18.3 Pulsed Field Ablation Market for Generators, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 18.4 Pulsed Field Ablation Market: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 19.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Product Components, 2021, 2023 and 2035
Figure 19.2 Pulsed Field Ablation Market for Cardiovascular Disorders using Catheters, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.3 Pulsed Field Ablation Market for Cardiovascular Disorders using Generators, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 19.4 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 20.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Application Area, 2021, 2023 and 2035
Figure 20.2 Pulsed Field Ablation Market for Cardiovascular Disorders using Ablation Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USDMillion)
Figure 20.3 Pulsed Field Ablation Market for Cardiovascular Disorders using Ablation and Mapping Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 20.4 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Application Area (Dynamic Dashboard Snippet)
Figure 21.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Source of Ablation, 2021, 2023 and 2035
Figure 21.2 Pulsed Field Ablation Market for Cardiovascular Disorders using PF Energy-based Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.3 Pulsed Field Ablation Market for Cardiovascular Disorders using PF and RF Energy-based Devices, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 21.4 Pulsed Field Ablation Market for Cardiovascular Disorders using PF and Cryo Energy-based Devices, Historical Trends (2021-2022) and Forecasted Estimates(2023-2035) (USD Million)
Figure 21.5 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Source of Ablation (Dynamic Dashboard Snippet)
Figure 22.1 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Geography, 2021, 2023 and 2035
Figure 22.2 Pulsed Field Ablation Market for Cardiovascular Disorders in North America, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.3 Pulsed Field Ablation Market for Cardiovascular Disorders in US, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.4 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.5 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates(2023-2035) (USD Million)
Figure 22.6 Pulsed Field Ablation Market for Cardiovascular Disorders in US: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.7 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.8 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.9 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.10 Pulsed Field Ablation Market for Cardiovascular Disorders in Canada: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.11 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.12 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.13 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.14 Pulsed Field Ablation Market for Cardiovascular Disorders in Europe: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.15 Pulsed Field Ablation Market for Cardiovascular Disorders in Asia-Pacific, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.16 Pulsed Field Ablation Market for Cardiovascular Disorders in China, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.17 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.18 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.19 Pulsed Field Ablation Market for Cardiovascular Disorders in China: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.20 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.21 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Product Components, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.22 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Application Area, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.23 Pulsed Field Ablation Market for Cardiovascular Disorders in Japan: Distribution by Source of Ablation, Historical Trends (2021-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.24 Pulsed Field Ablation Market for Cardiovascular Disorders: Distribution by Region (Dynamic Dashboard Snippet)
Figure 23.1 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Geography, 2018, 2023 and 2035
Figure 23.2 Pulsed Field Ablation Market for Oncological Disorders in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.3 Pulsed Field Ablation Market for Oncological Disorders in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.4 Pulsed Field Ablation Market for Oncological Disorders in Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 23.5 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Geography (Dynamic Dashboard Snippet)
Figure 24.1 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Product Components, 2018, 2023 and 2035
Figure 24.2 Pulsed Field Ablation Market for Oncological Disorders using Catheters, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 24.3 Pulsed Field Ablation Market for Oncological Disorders using Generators, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 24.4 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 25.1 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Type of Cancer, 2018, 2023 and 2035
Figure 25.2 Pulsed Field Ablation Market for Soft-tissue Ablative Cancers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.3 Pulsed Field Ablation Market for Pancreatic Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.4 Pulsed Field Ablation Market for Prostate Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.5 Pulsed Field Ablation Market for Non-Small Cell Lung Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.6 Pulsed Field Ablation Market for Esophageal Cancer, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 25.7 Pulsed Field Ablation Market for Oncological Disorders: Distribution by Type of Cancer (Dynamic Dashboard Snippet)
Figure 26.1 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Geography, 2020, 2023 and 2035
Figure 26.2 Pulsed Field Ablation Market for Respiratory Disorders in North America, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 26.3 Pulsed Field Ablation Market for Respiratory Disorders in Europe, Historical Trends (2020-2022) and Foreca sted Estimates (2023-2035) (USD Million)
Figure 26.4 Pulsed Field Ablation Market for Respiratory Disorders in Asia-Pacific, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 26.5 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Geography (Dynamic Dashboard Snippet)
Figure 27.1 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Product Components, 2019, 2023 and 2035
Figure 27.2 Pulsed Field Ablation Market for Respiratory Disorders using Catheters, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 27.3 Pulsed Field Ablation Market for Respiratory Disorders using Generators, Historical Trends (2020-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 27.4 Pulsed Field Ablation Market for Respiratory Disorders: Distribution by Product Components (Dynamic Dashboard Snippet)
Figure 28.1 Boston Scientific: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Figure 28.2 Medtronic: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Figure 28.3 Galvanize Therapeutics: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Figure 28.4 AngioDynamics: Pulsed Field Ablation Sales Forecast (2023-2035) (USD Million)
Figure 29.1 Concluding Remarks: Overall Market Landscape
Figure 29.2 Concluding Remarks: Recent Developments
Figure 29.3 Concluding Remarks: Patent Analysis
Figure 29.4 Concluding Remarks: Global Events Analysis
Figure 29.5 Concluding Remarks: Market Forecast and Opportunity Analysis

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

脈衝場消融（PFA）系統市場：現況分析與預測（2023-2030）

電生理學切除用導管的全球市場 - 市場規模(各市場區隔)，佔有率，法規，償付，治療，預測(～2033年)

電生理學導管消融術市場:開發平台報告(開發階段，市場區隔，地區·國家，法規途徑，主要企業)

電生理導管市場報告：2030 年趨勢、預測與競爭分析

電生理導管的全球市場 2023-2027

EP導管消融術的全球市場

FAQ

脈衝場消融市場:按治療領域.按產品組成.按應用領域.按消融源.按關鍵地區.主要參與者的市場份額:行業趨勢和全球預測2023-2035 年

Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Areas, Source of Ablation, and Key Geographical Regions: Market Share of Key Companies, Industry Trends and Global Forecasts, 2023-2035

目錄

第一章 前言

第二章 調查

調查方法

第三章 經濟及其他

項目特定的考慮因素

第 4 章執行摘要

第 5 章 簡介

第六章脈衝場消融裝置：市場情勢

第七章 產品競爭力分析

第 8 章脈衝場消融設備開發人員：詳細信息

公司簡介

第9章 脈衝場消融裝置研發

公司簡介

第 10 章 近期進展與舉措

第十一章 專利分析

第12章世界事件分析

第 13 章案例研究：脈衝場消融設備開發人員的潛在合作夥伴

第十四章市場影響分析：驅動因素、促進因素、機會、挑戰

第十五章全球脈衝場消融市場

第十六章脈衝場消融市場（按地區）

第十七章脈衝場消融市場（依治療領域）

第十八章脈衝場消融市場（依產品組成）

第十九章心血管疾病脈衝場消融市場（依產品組成）

第 20 章心血管脈衝場消融市場，依應用領域

第21章心血管脈衝場消融市場（依消融源）

第22章心血管脈衝場消融市場，依地區

第23章腫瘤疾病脈衝場消融市場

第 24 章腫瘤疾病脈衝場消融市場（依產品組成）

第 25 章按癌症類型劃分的腫瘤疾病脈衝場消融市場

第26章呼吸脈衝場消融市場

區域障礙

第27章呼吸脈衝場消融市場

按產品組件劃分的故障

第28章脈衝場燒蝕：主要產品銷售預測

主要進入者

第29章結論

第30章附錄1：表格數據

第三十一章 附錄2：公司與組織名單

INTRODUCTION

SCOPE OF THE REPORT

Surging Prevalence of Atrial Fibrillation, a Key Indication for Pulsed Field Ablation

Applications of Pulsed Field Ablation Technology for Cardiac Ablation

Pulsed Field Ablation Transforming Treatment for Oncology and Other Indications

Advantages of Pulsed Field Ablation Over Thermal Ablation

Current Pulsed Field Ablation Market Landscape

Currently Commercialized Pulsed Field Ablation Devices

Pulsed Field Ablation: Safety and Efficacy in Clinical Studies

Pulsed Field Ablation Market: Cardiovascular Disorders Marget Segment to hold the Largest Market Share

Leading Pulsed Field Ablation Companies

Recent Developments

RESEARCH METHODOLOGY

The secondary sources of information include:

KEY QUESTIONS ANSWERED:

Question 1: What is pulsed field ablation?

Question 2: How does PFA ablation work?

Question 3: How is PFA performed?

Question 4: What are the benefits of pulsed field ablation?

Question 5: What is pulsed magnetic field radiofrequency ablation?

Question 6: When will pulsed field ablation be available?

Question 7: What is the success rate of pulsed field ablation?

Question 8: Is FARAPULSE FDA approved?

Question 9: What is the estimated market growth rate (CAGR) for the pulsed field ablation market?

Question 10: Who are the leading companies in the pulsed field ablation market?

CHAPTER OUTLINES

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH

METHODOLOGY

3. ECONOMIC AND OTHER

PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. PULSED FIELD ABLATION DEVICES: MARKET LANDSCAPE

7. PRODUCT COMPETITIVENESS ANALYSIS

8. PULSED FIELD ABLATION DEVICE DEVELOPERS: DETAILED

COMPANY PROFILES

9. PULSED FIELD ABLATION DEVICE DEVELOPERS: TABULATED

第一章前言

第二章調查

第三章經濟及其他

第 5 章簡介

第七章產品競爭力分析

第9章脈衝場消融裝置研發

第 10 章近期進展與舉措

第十一章專利分析

第三十一章附錄2：公司與組織名單